Black Diamond Therapeutics, Inc. Stock OTC Markets
Equities
BDTX
US09203E1055
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
05-09 | Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-11 | Black Diamond Therapeutics, Inc. Announces Board and Committee Changes | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 321M 439M |
---|---|---|---|---|---|
Net income 2024 * | -93M -127M | Net income 2025 * | -121M -165M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.21
x | P/E ratio 2025 * |
-3.51
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.51% |
Managers | Title | Age | Since |
---|---|---|---|
Elizabeth Buck
FOU | Founder | 49 | 13-12-31 |
Mark Velleca
CEO | Chief Executive Officer | 60 | 21-08-08 |
David Epstein
FOU | Founder | 65 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Epstein
FOU | Founder | 65 | 13-12-31 |
Mark Velleca
CEO | Chief Executive Officer | 60 | 21-08-08 |
Ali Behbahani
BRD | Director/Board Member | 47 | 18-11-30 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- BDTX Stock
- BDTX Stock